These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 35990683)

  • 1. Colorectal cancer vaccines: The current scenario and future prospects.
    Jia W; Zhang T; Huang H; Feng H; Wang S; Guo Z; Luo Z; Ji X; Cheng X; Zhao R
    Front Immunol; 2022; 13():942235. PubMed ID: 35990683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.
    Zheng Y; Fu Y; Wang PP; Ding ZY
    Dis Markers; 2022; 2022():8270305. PubMed ID: 35211210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines for colorectal cancer: an update.
    Sarvizadeh M; Ghasemi F; Tavakoli F; Sadat Khatami S; Razi E; Sharifi H; Biouki NM; Taghizadeh M
    J Cell Biochem; 2019 Jun; 120(6):8815-8828. PubMed ID: 30536960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer.
    Yu YJ; Shan N; Li LY; Zhu YS; Lin LM; Mao CC; Hu TT; Xue XY; Su XP; Shen X; Cai ZZ
    Cancer Immunol Immunother; 2023 Jul; 72(7):2045-2056. PubMed ID: 36795124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of cancer vaccines against colorectal cancer.
    Jia W; Shen X; Guo Z; Cheng X; Zhao R
    Expert Opin Biol Ther; 2024 Apr; 24(4):269-284. PubMed ID: 38644655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colorectal cancer vaccines: Tumor-associated antigens
    Wagner S; Mullins CS; Linnebacher M
    World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of DNMTs increases neoantigen-reactive T-cell toxicity against microsatellite-stable colorectal cancer in combination with radiotherapy.
    Huang KC; Ke TW; Lai CY; Hong WZ; Chang HY; Lee CY; Wu CH; Chiang SF; Liang JA; Chen JY; Yang PC; Chen WT; Chuang EY; Chao KSC
    Biomed Pharmacother; 2024 Aug; 177():116958. PubMed ID: 38917760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates.
    Guo M; You C; Dou J
    Biomed Pharmacother; 2018 Nov; 107():1318-1325. PubMed ID: 30257347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches.
    Tan E; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189
    [No Abstract]   [Full Text] [Related]  

  • 13. Opportunities for immunotherapy in microsatellite instable colorectal cancer.
    Westdorp H; Fennemann FL; Weren RD; Bisseling TM; Ligtenberg MJ; Figdor CG; Schreibelt G; Hoogerbrugge N; Wimmers F; de Vries IJ
    Cancer Immunol Immunother; 2016 Oct; 65(10):1249-59. PubMed ID: 27060000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients.
    Wang D; Zhang H; Xiang T; Wang G
    Front Immunol; 2021; 12():762341. PubMed ID: 34721435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors.
    Lengyel CG
    Curr Drug Targets; 2021; 22(9):968-976. PubMed ID: 33970843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy combined with radiotherapy to reverse immunosuppression in microsatellite stable colorectal cancer.
    Wu C; Shao Y; Gu W
    Clin Transl Oncol; 2023 Jul; 25(7):1916-1928. PubMed ID: 36717514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on the use of immunotherapy in patients with colorectal cancer.
    Nguyen M; Tipping Smith S; Lam M; Liow E; Davies A; Prenen H; Segelov E
    Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):291-304. PubMed ID: 33138649
    [No Abstract]   [Full Text] [Related]  

  • 19. Recent advances in personalized cancer immunotherapy with immune checkpoint inhibitors, T cells and vaccines.
    Faghfuri E
    Per Med; 2024 Jan; 21(1):45-57. PubMed ID: 38088165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges.
    Link JT; Overman MJ
    Cancer J; 2016; 22(3):190-5. PubMed ID: 27341597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.